Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Nautilus Biotechnology Inc
NAUT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.96
0.39
24.84%
Últ. Act.: Oct 2, 7:59 PM
$2.23
0.66
42.07%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Nautilus Biotechnology Financials
Nautilus Biotechnology (NAUT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Nautilus Biotechnology Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $190.000K
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 8.33 percent increase over losses of $(0.12) per share
Benzinga Newsdesk
Earnings Scheduled For April 28, 2026
Benzinga Insights
PRO
Nautilus Biotechnology Q1 EPS $(0.12) Beats $(0.17) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 25 percent. This is a 7.69 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Nautilus Does Not Anticipate Material Revenue In 2026 From Early Access Program Engagement
Benzinga Newsdesk
PRO
Nautilus Biotechnology Q4 EPS $(0.11) Beats $(0.14) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 21.43 percent increase over losses of $(0.14) per share
Benzinga Newsdesk
Earnings Scheduled For October 28, 2025
Benzinga Insights
